August 24, 2016 06:27 AM EDT

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

John Carroll

Editor & Founder

AstraZeneca has completed another stage in its systematic retreat from the antibiotics business, selling a portfolio of marketed and experimental small molecule antibiotics to an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

As­traZeneca sells off more as­sets from its is­land of mis­fit drugs in $1.6B Pfiz­er deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva